IMMUNOHISTOCHEMICAL LOCALIZATION OF EPIDERMAL GROWTH FACTOR RECEPTOR AND C-erbB-2 ONCOGENE PRODUCT IN DEVELOPING HUMAN PLACENTA

Cytologic locailzation of epidermai growth factor receptor (EGF-R) and C-erbB2oncogene product in normal developing placenta ovas studied by avidin/biotin immunoperoxidase techniques.Both proteins were predominantly expressed in the villous syncytiotrophoblasts but not in the cytotrophoblasts.The immunoreactive intensity for EGF-R decreased with the development of pregnancy.Concerning the intermediate trophoblasts in cell islands and cell columns,both proteins were more easily detected in the cells distal to the villous stroma than in the juxtastromal cells.These findings suggest that EGF-R and C-erbB-2 may play a significant role in the induction and regulation of differentiated trophoblast function

Study of differential polymerase chain reaction of C-erbB-2 oncogene amplification in gastric cancer

AIM To study the significance of C-erbB-2 oncogene amplification in gastric cancer.METHODS C-erbB-2 oncogene amplification was examined by using differential polymerase chain reaction (dPCR) in surgical and endoscopic specimens of 83 cases of gastric cancer and 101 metastatic lymph nodes.RESULTS C-erbB-2 amplification was found in 28.9% (24/ 83) surgical specimens and 20.5% (17/ 83) endoscopic ones of gastric cancer patients. The amplification was significant in both types of specimens of advanced cancer cases (P＜0.05) and surgical specimens with lymph node metastasis (P＜0.01). The incidence of C-erbB-2 amplification in lymph nodes with metastasis was higher than in primary sites (surgical specimens, P＜0.05). The patients with amplification tumors had poorer 5-year survival rates than those with unamplification ones in the early cancers and well to moderately differentiated adenocarcinomas (P＜0.05). The same surgical samples were tested again by Southern blot hybridization to ascertain C-erbB-2 amplification, and the positive rate of C-erbB-2 amplification (15.7%) was lower than that of dPCR (28.9%, P＜0.05).CONCLUSION Examining C-erbB-2 amplification by dPCR is a quick, simple, reliable and independent method, and is helpful in predicting prognosis and metastatic potential of gastric cancer.

Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-β1 in human pancreatic ductal adenocarcinoma

Objective: To detect the relations of c-erbB-2 onco-gene protein, epidermal growth factor receptor (EG-FR) and transforming growth factor-β1 (TGF-β1)to the progression or metastasis of pancreatic carci-noma.Methods: Using streptavidinbiotin complex (SABC)method, c-erbB-2 oncongene protein, we examinedimmunohistochemically EGFR and TGF-β1 expres-sions in wax-tissue sections from 10 individuals withnormal pancreas (NP), 13 patients with chronic pan-creatitis (CP) and 36 patients with pancreatic ductaladenocarcinoma (PC).Results: The positive expression rates of c-cerbB-2oncogene protein, EGFR and TGF-β1 in the NP, CPand PC groups were 0, 0, 10%; 7.7%, 7.7%,7.7%; and 41.7%, 50.0%, 44.4%, respectively.The positive expression rates of the three specific pro-teins increased more significantly in the PC groupthan in the NP and CP groups (P【0.05). The indi-vidual expression of c-erbB-2, EGFR and TGF-β1was not related to the age and sex of the patients aswell as the site, size and histopathological grade oftumors (P】0.05), but to the clinical stage of tumors(P【0.01). The coexpression rate of the three pro-teins was 27.8 % (10/36). This coexpression in thePC group was correlated with the histopathologicalgrades and clinical stages of tumors (P【0.01).Conclusion: Detection of c-erbB-2 oncogene protein,EGFR, and TGF-β1 expressions in pancreatic tissueis helpful to judge the malignancy, progression, andmetastasis of PC.

转录因子MYB转录调控MTFR2通过DNA损伤修复促进胃癌细胞化疗耐药性

目的探究v-myb禽成髓细胞病病毒癌基因同源物(MYB)转录调控线粒体裂变调节因子2(MTFR2)对胃癌(GC)细胞顺铂(DDP)耐药性的影响及分子作用机制。方法TCGA数据库分析GC中差异mRNA并预测上游调控分子,qRT-PCR检测MTFR2和MYB的表达,双荧光素酶和染色质免疫共沉淀(ChIP)实验验证MTFR2和MYB的调控关系,细胞计数盒8(CCK-8)检测细胞活力并计算IC_(50)值,流式细胞术检测细胞周期和细胞凋亡,彗星实验检测DNA损伤,蛋白质免疫印迹法检测DNA损伤相关蛋白(γ-H2AX、ATM、p-ATM)的表达。结果MTFR2在GC组织和细胞中显著高表达,敲低MTFR2能够降低细胞增殖,阻滞S期,诱导细胞凋亡,促进DNA损伤和DDP敏感性。生信预测MTFR2存在上游转录因子MYB,MYB在GC组织和细胞中的表达显著上调,双荧光素酶和ChIP验证了MTFR2启动子区域与MYB的结合关系。回复实验发现进一步过表达MTFR2能够逆转敲低MYB对GC细胞增殖和DDP耐药性的抑制作用。结论MYB上调MTFR2的表达通过DNA损伤途径促进GC细胞增殖和DDP耐药,表明靶向MYB/MTFR2调控轴可能是克服GC DDP耐药性的潜在途径。

乳腺癌超声征象与ER,PR,C-erbB-2,Ki-67表达的相关性研究

目的探讨乳腺癌超声征象和雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、C-erbB-2、Ki-67表达的相关性。方法选取120例乳腺癌患者资料,比较不同超声征象间ER、PR、C-erbB-2、Ki-67阳性表达的差异,并分析其相关性。结果ER阳性者中无区域淋巴结转移及0~I级血流信号比例更高,PR阳性者中无区域淋巴结转移及纵横比<1比例更高,C-erbB-2阳性者中直径≥2 cm及纵横比≥1比例更高,Ki-67阳性中Ⅱ~Ⅲ级血流信号比例更高。区域淋巴结转移与ER、PR的阳性表达呈负相关,C-erbB-2阳性表达与纵横比≥1呈正相关,Ki-67阳性表达与纵横比≥1及富血供呈正相关,上述所有结果差异均有统计学意义(P<0.05)。结论乳腺癌患者的ER、PR、C-erbB-2及Ki-67的表达与部分超声征象存在一定相关性,能在一定程度上协助临床制定诊疗方案及判断患者预后。

Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma

BACKGROUND: Molecular cytogenetics of oncogene HER-2 amplification in primary hepatocellular carcinoma (HCC) is still unknown. The aim of this study was to in vestigate the frequency of HER-2 oncogene amplification in primary HCC and its relations to clinicopathological pa rameters and prognosis. METHODS: Forty-two surgical samples from patients with primary HCC were detected for their HER-2 oncogene am plification. The number of chromosome 17 and their ratio were tested by dual fluorescence in situ hybridization (FISH) technique, and then the correlations between HER-2 amplification, clinicopathological characteristics and prog nosis were analyzed statistically. RESULTS: HER-2 oncogene amplification was detected in 9 (21.4%) of the 42 primary HCCs, including 4 patient with high copy (HC) (9.5%) and 5 patients with low copy (LC) (11.9%). HER-2 amplification was associated signifi cantly with tumor size and postoperative survival time o HCC patients (P<0.05), and the presence of HER-2 gene amplification was correlated with postoperative relapse (P— 0.257), but not related to sex, age, AFP level, HBV infec tion, histopathological grading and clinical staging of HCC patients (P>0.05). The HER-2 oncogene copy was exa mined in 31 (73.8%) of the 42 primary HCCs, consisting of 9 patients with HER-2 amplification (21.4%) and 22 pa tients with aneuploidy (52.4%). No significant relation were observed between the HER-2 oncogene copy, patien sex, tumor size, histopathological grading, clinical stag ing, postoperative relapse and survival time (P >0.05); bu the HER-2 oncogene copy was correlated significantly to age, AFP level and HBV infection (P <0.05). CONCLUSIONS: There are a lower frequency of HER-2 oncogene amplification and a higher frequency of chromo- some 17 aneuploidy in primary HCC. HER-2 oncogene amplification may be involved in the development and pro- gression of large HCC in some patients, and seems to be a valuably independent prognostic factor predicting the re- currence and poor survival in patients with large HCC.

Expression of bcl-2 oncogene in gastric precancerous lesions and its correlation with syndromes in traditional Chinese medicine

AIM: To observe the protein and mRNA expression of bcl-2 oncogene in gastric precancerous lesions (GPL) and to analyze its correlation with syndromes in traditional Chinese medicine (TCM). METHODS: Sixty-seven patients with GPL confirmed by gastroscopy and pathology were studied,including 39 cases of moderate gastric mucosal dysplasia,19 cases of severe gastric mucosa dysplasia, 9 cases of incomplete colon metaplasia. In syndrome differentiation of TCM,17 cases belonged to the syndrome of qi and yin deficiency of the spleen and stomach complicated by qi stagnation, 21 cases belonged to the syndrome of qi and yin deficiency of the spleen and stomach complicated by stomach heat, 29 cases belonged to the syndrome of qi and yin deficiency of the spleen and stomach complicated by blood stasis. Protein and mRNA expression of bcl-2 oncogene were detected by labeled streptavidin biotin (LSAB) immunohist-ochemistry and in situ hybridization respectively. RESULTS: Abnormal expression of protein and mRNA on bcl-2 oncogene was found in GPL,which increased gradually with the course of lesions. In moderate and severe gastric mucosal dysplasia and incomplete colon metaplasia,there was no difference in the expression of bcl-2 oncogene (P>0.05).In different accompanying syndromes, the expression of protein and mRNA on bcl-2 oncogene increased gradually in the following order: deficiency of both qi and yin of the spleen and stomach accompanying qi stagnation→stomach heat→blood stasis. In GPL, compared with accompanying blood stasis, there was an obvious difference in the expression of bcl-2 oncogene between the syndrome of qi and yin deficiency of the spleen and stomach and accompanying stomach heat, so did accompanying qi stagnation (the level of protein: X2=8.45, P<0.05;the level of mRNA: X2=7.35, P<0.05). CONCLUSION: Apoptosis-associated bcl-2 oncogene is abnormally expressed in GPL,which correlates with different accompanying syndromes in TCM.

Identification of APEX2 as an oncogene in liver cancer

BACKGROUND DNA damage is one of the critical contributors to the occurrence and development of some cancers.APEX1 and APEX2 are the most important molecules in the DNA damage,and APEX1 has been identified as a diagnostic and prognostic biomarker in liver hepatocellular carcinoma(LIHC).However,the expression of APEX2 and its functional mechanisms in LIHC are still unclear.AIM To examine the expression of APEX2 and the potential mechanism network in LIHC.METHODS We conducted a pan-cancer analysis of the expression of APEX1 and APEX2 using the interactive TIMER tool.GEO datasets,including GSE14520,GSE22058,and GSE64041,were used to compare the APEX2 expression level in tumor tissues and adjacent non-tumor tissues.Then,we calculated the 5-year survival rate according to the web-based Kaplan-Meier analysis.We included the TCGA liver cancer database in GSEA analysis based on the high and low APEX2 expression,showing the potential mechanisms of APEX2 in LIHC.After that,we conducted Pearson correlation analysis using GEPIA2.Next,we performed quantitative polymerase chain reaction(qPCR)assay to examine the APEX2 levels in normal liver cell line LO2 and several liver cancer cell lines,including HepG2,Huh7,SMMC7721,and HCCLM3.APEX2 in HCCLM3 cells was knocked down using small interfering RNA.The role of APEX2 in cell viability was confirmed using CCK-8.Dualluciferase reporter assay was performed to examine the promoter activity of CCNB1 and MYC.RESULTS APEX1 and APEX2 are both highly expressed in the tumor tissues of BLCA,BRCA,CHOL,COAD,ESCA,HNSC,LIHC,LUAD,LUSC,READ,and STAD.APEX2 overexpression in LIHC was validated using GSE14520,GSE22058,and GSE64041 datasets.The survival analysis showed that LIHC patients with high expression of APEX2 had a lower overall survival rate,even in the AJCC T1 patients.High level of APEX2 could indicate a lower overall survival rate in patients with or without viral hepatitis.The GSEA analysis identified that kinetochore and spindle microtubules are the two main cellular components of APEX2 in GO Ontology.APEX2 was also positively associated with molecular function regulation of chromosome segregation and DNA replication.The results of KEGG analysis indicated that APEX2 expression was positively correlated with cell cycle pathway and pro-oncogenic MYC signaling.Pearson correlation analysis showed that APEX2 had a significant positive correlation with CCNB1 and MYC.APEX2 level was higher in liver cancer cell lines than in normal liver LO2 cells.Small interfering RNA could knock down the APEX2 expression in HCCLM3 cells.Knockdown of APEX2 resulted in a decrease in the viability of HCCLM3 cells as well as the expression and promoter activity of CCNB1 and MYC.CONCLUSION APEX2 is overexpressed in LIHC,and the higher APEX2 level is associated with a worse prognosis in overall survival.APEX2 is closely involved in the biological processes of chromosome segregation and DNA replication.APEX2 expression is positively correlated with the pro-oncogenic pathways.Knockdown of APEX2 could inhibit the cell viability and CCNB1 and MYC pathways,suggesting that APEX2 is an oncogene in LIHC,which could be a potential pharmaceutic target in the anti-tumor therapy.

HER2/c-erbB-2蛋白在胃癌组织中的表达及临床治疗指导价值

目的探究胃癌患者中HER2/c-erbB-2蛋白表达特征,为治疗和预后的指导价值作进一步研究。方法我院于2020年7月至2021年7月收治的100例胃癌患者被选为受试对象,治疗方案均为手术治疗,术中选择病灶及周围组织(距离病灶直径超于3 cm),采用免疫组化法对组织表达能力作检验;根据患者病理特点及随访资料,比较阳性表达率与胃癌病理特点、生存期之间的关系。采用Cox回归模型进行预后生存影响因素分析,采用Kaplan-Merier进行生存分析。结果淋巴结转移患者的HER2/c-erbB-2阳性率高于未转移者,TNM分期的Ⅲ-Ⅳ期HER2/c-erbB-2阳性率高于Ⅰ-Ⅱ期(P<0.05);病灶组织HER2/c-erbB-2阳性率高于癌旁组织(P<0.05);淋巴结转移、TNM分期和HER2/c-erbB-2为影响胃癌患者预后生存的独立危险因素(P<0.05)。HER2/c-erbB-2蛋白表达阳性患者生存期短于阴性患者(P<0.05)。结论HER2/c-erbB-2蛋白在胃部肿瘤表达程度高,具有缩短生存期的作用,对胃癌的靶向治疗有指导意义。

THE EXPRESSIONS OF HBV X GENE AND ets-2, IGF-Ⅰ, c-myc AND N-ras ONCOGENES IN HUMAN HEPATOCELLULAR CARCINOMA AND TUMOR-ADJACENT TISSUES

The expressions of HBV X gene and ets-2, IGF-I, c-myc and N-ras were studied in 7 pairs of human primary hepatocellular carcinoma (PHC) and tumor-adjacent tissues, using RNA hybridization and im-munoblot methods. The results showed that specific 17 and 28 kD HBV X gene products (HBxAg) were existed in a portion of PHC and tumor-adjacent tissues. The 17 kD HBxAg was detected in the sera of 3 patients who also had 17 kD HBxAg in their liver tissues. Multiple expressions of oncogenes such as ets-2, c-myc and N-ras were observed in PHC and tumor-adjacent tissues that had HBxAg expressed, indicating HBxAg might function as a transactivator in the course of intracellular proto-oncogene activation. It is also observed that in some tumor-adjacnet tissues the expressions of ets-2, c-myc and N-ras were higher than those in corresponding PHC. The relationship of HBxAg to the expression of est-2, IGF-Ⅱ, c-myc and their possible roles in the carcinogenesis of PHC are discussed.

针灸预处理对胃溃疡大鼠胃黏膜状态及Gli 1/Gli 2/Sufu信号通路的影响研究

目的:研究针灸预处理对胃溃疡大鼠胃黏膜状态及胶质瘤相关癌基因同源物1(Glioma-associated oncogene homolog 1,Gli1)/胶质瘤相关癌基因同源物2(Glioma-associated oncogene homolog 2,Gli2)/丝氨酸/苏氨酸激酶Fused抑制物(Sufu)信号通路的影响,探究针灸预防胃黏膜损伤的作用机制,为针灸在临床治疗胃溃疡疾病提供实验依据和理论支撑。方法:52只大鼠随机分为正常组、模型组、灸预处理组、针刺预处理组,每组13只。正常组、模型组只做固定;对灸预处理组和针刺预处理组艾灸中脘、足三里穴,每穴20min,1次/d,连续灸8d。之后对灸预处理组和针刺预处理组大鼠进行无水乙醇+阿司匹林混悬液灌胃造模。观察大鼠一般情况及胃黏膜组织病理学变化;酶联免疫吸附实验(ELISA)法检测大鼠血清中超氧化物歧化酶(SOD)、丙二醛(Malondialdehyde,MDA)、谷胱甘肽过氧化物酶(GPX)浓度,蛋白质印迹法(Western blot)分析大鼠胃黏膜组织Gli 1、Gli 2、Sufu蛋白表达。结果:模型组可见上皮细胞结构破坏不完整,胃黏膜组织损伤明显,UI指数评分显著高于正常组(P<0.05)。与正常组比较,模型组大鼠血清MDA、GPX浓度升高(P<0.05),SOD浓度降低(P<0.05);与模型组相比,针灸预处理组MDA、GPX浓度降低(P<0.05),SOD浓度增加(P<0.05);与正常组比较,模型组大鼠Gli1、Gli2、Sufu蛋白表达明显升高(P<0.05);与模型组比较,针灸预处理组大鼠Gli1、Gli2、Sufu蛋白表达明显降低(P<0.05)。结论:针灸预处理能改变胃溃疡大鼠胃黏膜状态,其机制可能与Gli 1/Gli 2/Sufu信号通路活化有关。

子宫内膜癌C-erbB-2、ETS1和p53的表达及临床意义

目的:探讨子宫内膜癌组织中C-erbB-2、成红细胞特异性转化因子1(ETS1)及p53表达及临床意义。方法:选择2019年1月至2020年12月我院收治的疑似子宫内膜癌患者90例作为研究对象,所有入选者均检测C-erbB-2、ETS1及p53阳性情况。以病理检查结果作为“金标准”,分析C-erbB-2、ETS1及p53诊断子宫内膜癌的准确度、灵敏度、特异度、阳性预测值、阴性预测值,并计算各指标单项以及联合诊断结果与病理检查结果的一致性。结果:90例疑似子宫内膜癌患者经病理结果确诊52例为子宫内膜癌,38例为良性病变;C-erbB-2、ETS1及p53联合诊断的灵敏度94.23%(49/52)、特异度94.74%(36/38)、准确度94.44%(85/90)、阳性预测值96.08%(49/51)、阴性预测值92.31%(36/339)均高于各项指标单独检测,差异有统计学意义(P<0.05)。C-erbB-2诊断结果与病理检查结果一致性较差(Kappa=0.312,P<0.05),ETS1诊断结果与病理检查结果一致性理想(Kappa=0.297,P<0.05),p53诊断结果与病理检查结果一致性理想(Kappa=0.323,P<0.05),联合诊断结果与病理检查结果一致性极好(Kappa=887,P<0.05)。结论:C-erbB-2、ETS1及p53的异常表达能够反映子宫内膜癌患者病情变化,联合检测在早期诊断中准确度、灵敏度、特异度均较高,与病理检查结果一致性极好,在临床有较高的应用价值。

SIRT2在抗肿瘤中的研究进展

沉默信息调节因子2(silent information regulator 2,SIRT2)作为sirtuins蛋白家族成员广泛存在于真核生物之中,是具备调节生物生成和代谢调控过程作用的Ⅲ类去乙酰化酶,参与调控细胞分化、新陈代谢、衰老、DNA损伤修复、维持基因组完整性以及肿瘤的发生等。SIRT2的异常表达与多种肿瘤的发生发展具有密切关系,例如其在乳腺癌、宫颈癌、肺癌等恶性肿瘤方面的研究进展,SIRT2在发挥原癌基因作用的基础上,也发挥抑癌基因的作用。该文主要就SIRT2在肿瘤发生发展中的分子机制及其研究进展进行综述,以期为研究者开发肿瘤治疗药物提供新视野。

Correlation of Kif2a and HPK1 expression in breast cancer with the oncogene and drug resistance gene expression

Objective: To investigate the correlation of Kif2a and HPK1 expression in breast cancer with the oncogene and drug resistance gene expression. Methods: A total of 91 patients with breast cancer and 85 patients with breast adenoma who accepted surgical treatment in our hospital between August 2016 and February 2018 were selected, and the breast cancer tissues and breast adenoma tissues were collected respectively as the research samples. Fluorescence quantitative PCR method was used to detect the expression of Kif2a and HPK1 genes as well as oncogenes and drug resistance genes in sample tissues, and Pearson test was used to evaluate the inner link of Kif2a and HPK1 gene expression in breast cancer tissue with oncogene and drug resistance gene expression. Results: Kif2a mRNA expression in breast cancer tissues was higher than that in breast adenoma tissues whereas HPK1 mRNA expression was lower than that in breast adenoma tissues;oncogenes DEK, iASPP-SV, Stat3, MDM2 and Fra-1 mRNA expression were higher than those in breast adenoma tissues;drug resistance genes ESR1, MDR1, P-gp, MRP1 and GST- mRNA expression were higher than those in breast adenoma tissues whereas BCRP mRNA expression was lower than that in breast adenoma tissues. Correlation analysis showed that the Kif2a and HPK1 gene expression in breast cancer tissues were directly correlated with the expression of oncogenes and drug resistance genes. Conclusion: Kif2a gene is abnormally highly expressed whereas HPK1 gene is abnormally lowly expressed in breast cancer tissues, and they are involved in the regulation of oncogene and drug resistance gene expression.

活心丸对急性心肌梗死病人血清GDF-15、ESM-1、sST2水平及心功能的影响

目的:观察活心丸对急性心肌梗死病人血清生长分化因子-15(GDF-15)、内皮细胞特异性分子1(ESM-1)、可溶性致癌抑制因子2(sST2)水平及心功能的影响。方法:选取2020年6月—2023年6月在廊坊市人民医院治疗的94例急性心肌梗死病人,随机分为对照组和治疗组,各47例。对照组口服阿司匹林片、替格瑞洛片、阿托伐他汀钙片、酒石酸美托洛尔片进行治疗,治疗组在对照组基础上口服活心丸。比较两组临床疗效、心功能、心肌酶谱指标、血清GDF-15、ESM-1、sST2水平、生活质量及不良反应。结果:治疗组治疗2周后总有效率为93.62%,高于对照组的78.72%,差异有统计学意义(P<0.05)。治疗2周后,两组左室质量指数(LVMI)、左室重构指数(LVRI)及血清心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)、肌酸激酶(CK)、GDF-15、ESM-1、sST2水平均较治疗前降低(P<0.05),且治疗组降低程度优于对照组(P<0.05);左室射血分数(LVEF)及西雅图心绞痛量表(SAQ)各项评分均较治疗前升高(P<0.05),且治疗组升高程度优于对照组(P<0.05);6 min步行距离较治疗前延长(P<0.05),且治疗组6 min步行距离较对照组延长(P<0.05)。治疗组和对照组不良反应总发生率比较差异无统计学意义(8.51%与14.89%,P>0.05)。结论:活心丸治疗急性心肌梗死病人,可降低病人血清GDF-15、ESM-1、sST2及心肌酶谱指标水平,改善心功能及生活质量,提高临床疗效,且安全性良好。

乳腺癌MRI形态学表现与C-erbB-2表达的相关性研究

目的 探讨乳腺癌MRI形态学表现与C erbB 2癌基因的相关性。方法 对 78例乳腺癌和 42例乳腺纤维腺瘤患者术前行乳腺MR扫描 ,分析乳腺癌的MRI形态学表现。术后标本行免疫组织化学染色测定肿瘤细胞C erbB 2的表达情况 ,并分析与相应病灶MRI表现的关系。结果 乳腺癌MRI多表现为边缘形态不规则或毛刺状边缘、边界模糊、瘤内有坏死。乳腺癌内部坏死与癌细胞C erbB 2阳性表达呈显著正相关 (r=0 .2 7,P <0 .0 5 ) ;而边界模糊、毛刺状边缘与癌细胞C erbB 2表达情况无显著相关性 (r =0 .11,r=-0 .13 ,P >0 .0 5 )。结论 乳腺癌MRI形态学表现与分子生物学指标C erbB 2之间存在一定的相关性。乳腺癌的MRI表现从一定程度上反映了癌细胞的生物学行为和预后 ,为临床治疗方案的选择提供客观依据。

乳腺癌ER、PR、c-erbB-2和nm23表达的相关性及临床病理意义

目的研究乳腺癌癌基因c-erbB-2、抑癌基因nm23和雌激素(ER)、孕激素受体(PR)的表达及意义。方法应用免疫组化SP法检测126例浸润性乳腺癌c-erbB-2、nm23及雌、孕激素受体的表达。结果①ER的表达与癌组织分化、肿瘤TNM分期及肿瘤大小呈负相关,小叶癌ER阳性率高于导管癌,而与患者年龄及淋巴结转移无显著相关性。②PR的表达与癌组织分化、肿瘤TNM分期呈负相关,与肿瘤大小、肿瘤类型、患者年龄及淋巴结转移无显著相关性。③c-erbB-2表达与肿瘤TNM分期、组织学分级、肿瘤大小及淋巴结转移呈正相关,与患者年龄、肿瘤类型无显著相关性。④乳腺癌Ⅰ期nm23表达的阳性率及阳性强度明显高于Ⅱ、Ⅲ期癌,nm23表达与组织学分级、淋巴结转移呈负相关,而与肿瘤大小及类型无显著相关性。⑤ER与PR表达呈正相关;nm23表达与ER、PR表达呈正相关,与c-erbB-2表达呈负相关;癌组织c-erbB-2与ER表达呈负相关,与PR表达无显著相关性。结论ER、PR、c-erbB-2及nm23的联合检测能够较好地反映乳腺癌病理生物学特征。

c-erbB-2、VEGF和组织蛋白酶D在胃癌中的表达及其相关性

目的 :探讨癌基因c erbB 2、血管内皮生长因子 (VEGF)和组织蛋白酶D(Cath D)在胃癌中的表达及其与胃癌生物学行为的关系。方法 :采用免疫组织化学 (S P)法 ,检测了 10 2例胃癌手术标本中c erbB 2、VEGF及Cath D的表达 ,同时观察了网状纤维分布与c erbB 2、Cath D之间的关系 ,并将检测结果与跟踪随访资料进行了综合分析。结果 :10 2例胃癌组织中c erbB 2表达阳性率为 38 2 4 % (39/ 10 2 ) ,与胃癌浸润深度 (P <0 0 5 )、淋巴结转移 (P <0 0 5 )密切相关 ;VEGF表达阳性率为 5 0 %(5 1/ 10 2 ) ,与胃癌浸润深度 (P <0 0 1)、生长方式 (P <0 0 1)、淋巴结转移 (P <0 0 1)密切相关 ;Cath D表达阳性率为81 37% (83/ 10 2 ) ,与胃癌浸润深度 (P <0 0 5 )、生长方式 (P <0 0 5 )、淋巴结转移 (P <0 0 5 )及脉管内有无癌栓 (P <0 0 5 )有关。对生存期分析显示 :Cath D、VEGF、c erbB 2阳性患者预后差 ,5年生存率低于阴性表达患者。结论 :c erbB 2、VEGF及Cath D与胃癌的生长、浸润、转移、预后有密切关系 。

Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义

背景与目的:细胞增殖抗原标记物(Ki67)为细胞增殖的一个重要生物学指标。本研究旨在探讨Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中的表达及其与临床病理因素的相关性。方法:用免疫组化方法检测151例乳腺癌组织中Ki67和其他生物学指标的表达,并与临床病理因素进行相关性分析。结果:Ki67在乳腺癌组织中的阳性率为74.8%(113/151)。Ki67表达与乳腺癌临床分期有关(P<0.05),而与患者年龄、肿瘤大小、淋巴结转移状况无显著性相关(P>0.05);Ki67表达与P53、C-erbB-2表达呈正相关(P<0.05),而与VEGF表达无显著性相关;Ki67和VEGF的共表达与肿瘤大小和临床分期有关(P<0.05)。结论:Ki67阳性表达可作为评价乳腺癌发生、发展的生物学指标,联合VEGF检测更有助于乳腺癌临床分期的判断。

人乳头状瘤病毒HPV-CIP5及癌基因c-erbB-2与宫颈癌的关系

目的：研究人乳头状瘤病毒ＨＰＶ－ＣＩＰ５及癌基因ｃ－ｅｒｂＢ－２与宫颈癌的关系。方法：应用免疫组化ＳＰ法对宫颈鳞癌７６例、腺癌２２例、宫颈上皮内瘤变ｃｅｒｖｉｃａｌｉｎｔｒａｅｐｉｔｈｅｌｉａｌｎｅｏｐｌａｓｉａ（ＣＩＮ）１０例及正常子宫颈粘膜２０例行ＨＰＶ－ＣＩＰ５及ｃ－ｅｒｂＢ－２染色。结果：上述各组织ＨＰＶ－ＣＩＰ５阳性率分别为７２４％（５５／７６）、４０９％（９／２２）、８０％（８／１０）、３５％（７／２０），其中鳞癌及ＣＩＮ中明显高于正常宫颈组织的表达（Ｐ＜００１），腺癌与正常宫颈组织表达无明显差异（Ｐ＞００５）；各组织中ｃ－ｅｒｂＢ－２阳性率分别为５２６％（４０／７６）、５９１％（１３／２２）、２０％（２／１０）、１５％（３／２０），其中鳞癌、腺癌中明显高于正常宫颈组织中表达（Ｐ＜００１）；在鳞癌ＨＰＶ－ＣＩＰ５与ｃ－ｅｒｂＢ－２同时表达３８例，占５０％（３８／７６），即４０例ｃ－ｅｒｂＢ－２阳性患者中有３８例ＨＰＶ－ＣＩＰ５同时呈现阳性；在腺癌ＨＰＶ－ＣＩＰ５与ｃ－ｅｒｂＢ－２同时表达８例，占３６３％（８／２２），即：９例ＨＰＶ－ＣＩＰ５阳性患者中有８例ｃ－ｅｒｂＢ－２同时呈现?